NephrosNEPH -0.83%62 Pretax Margin % is 2.69% as of Mar. 2026. GuruFocus rates NEPH with a GF Score™ of 62/100 and a GF Value™ of $2.87 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Nephros ranks better than 53% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Nephros's Pre-Tax Income for the
three
months ended in Mar. 2026 was $0.14 Mil. Nephros's Revenue for the
three
months ended in Mar. 2026 was $5.21 Mil. Therefore, Nephros's pretax margin for the quarter that ended in Mar. 2026 was 2.69%.
The historical rank and industry rank for Nephros's Pretax Margin % or its related term are showing as below:
NEPH'
s Pretax Margin % Range Over the Past 10 Years
Min: -130.69 Med: -37.91 Max: 6.42
Current: 4.12
NEPH's Pretax Margin % is ranked better than 53% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.4
vs NEPH: 4.12
Nephros (NAS:NEPH) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Nephros Pretax Margin % Related Terms
Nephros Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Nephros's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NEPH vs MLSS, RGNT, HBIO: Pretax Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nephros's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros Pretax Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Nephros's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nephros (NEPH) has a Pretax Margin % of 2.69% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nephros and its competitors. According to the industry distribution chart, Nephros ranks #384 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 47%.
Is Nephros' Pretax Margin % too high?
Nephros' current Pretax Margin % is 2.69%. The Medical Devices & Instruments industry median Pretax Margin % is 2.40. Nephros' value of 2.69% is 12.1% above this industry median. Based on the distribution chart, Nephros ranks #384 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nephros has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Pretax Margin % compare to MLSS and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #384 out of 817 companies for Pretax Margin %. This puts Nephros in the upper half of its industry. The industry median Pretax Margin % is 2.40. Nephros' value of 2.69% is 12.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Devices & Instruments company?
The median Pretax Margin % among Medical Devices & Instruments companies is 2.40, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephros's current Pretax Margin % of 2.69% is 12.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Nephros and its competitors. For the Medical Devices & Instruments industry, the median Pretax Margin % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current Pretax Margin % is 2.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.87, compared to a current price of $3.58 — trading 24.7% above its estimated fair value. The current Pretax Margin % is 2.69% and 12.1% above the Medical Devices & Instruments industry median of 2.40. Nephros' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Nephros (NEPH), the current Pretax Margin % is 2.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nephros (NEPH) Overvalued in 2026?
Based on GuruFocus' analysis, Nephros stock appears to be overvalued.
The current stock price of $3.58 is trading 24.7% above its estimated GF Value™ of $2.87.
GuruFocus considers Nephros to be Modestly Overvalued.
Key valuation signals for NEPH:
Pretax Margin %: 2.69%
GF Value™: $2.87 vs. price of $3.58 (24.7% above fair value)
Industry Position: 12.1% above the Medical Devices & Instruments median (#384 of 817)
No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
62GF Score
Get the complete analysis for NEPH
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEPH has been successfully added to your 
